外泌体非编码RNA在骨肉瘤转移中的研究进展

胡雪梅; 潘宝龙; 白萤萤; 杨洋

doi:10.16766/j.cnki.issn.1674-4152.003849

外泌体非编码RNA在骨肉瘤转移中的研究进展

doi: 10.16766/j.cnki.issn.1674-4152.003849

昆明医科大学第六附属医院医学检验科，云南玉溪 653100

基金项目:

国家自然科学基金项目 81960487

详细信息

通讯作者:
潘宝龙，E-mail：pbl1210@126.com

中图分类号: R738.1
计量
- 文章访问数: 25
- HTML全文浏览量: 18
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2024-05-11
- 网络出版日期: 2025-02-13

Research progress of exosome-deriveds non-coding RNA in osteosarcoma metastasis

Department of Clinical Laboratory, the Sixth Affiliated Hospital of Kunming Medical University, Yuxi, Yunnan 653100, China

摘要

摘要: 骨肉瘤(OS)是一种好发于儿童和青少年的原发性骨恶性肿瘤，其具有进展快、恶性程度高、易转移的特点。骨肉瘤的转移常在疾病早期就已发生，主要转移部位为肺部，是治疗失败和预后差的主要原因之一。外泌体是由多种细胞分泌的、能在多种体液中找到的细胞外囊泡，直径为40~160 nm，具有细胞间通讯以及维持细胞结构的功能。外泌体中包含多种生物活性物质，如蛋白质、脂质、mRNA和ncRNA等，其中ncRNA在通过细胞间通讯致使骨肉瘤远端转移方面发挥着十分关键的作用。MiRNA、lncRNA以及circRNA是目前研究较多的ncRNA，其能在多个分子水平对影响骨肉瘤转移的相关分子进行调控。外泌体ncRNA在骨肉瘤中表达水平可发生升高或降低，能通过提高骨肉瘤细胞的侵袭和迁移能力、诱导上皮间充质转化、促进血管生成、激活相关信号通路等调控骨肉瘤的进展与转移。在骨肉瘤耐药方面，外泌体能够通过传递ncRNA，诱导敏感细胞耐药。同时，由于外泌体自身独特的生物学特性，作为骨肉瘤诊断、预后和转移等生物标志物方面非常具有应用潜力。近年来，外泌体ncRNA在骨肉瘤的机制研究与临床应用中发挥着十分重要的作用。本文就外泌体ncRNA在骨肉瘤转移、化疗耐药以及作为潜在相关生物标志物中的作用进行综述，以期为骨肉瘤转移的机制研究、治疗及预后等提供参考。
- 非编码RNA /
- 骨肉瘤 /
- 转移 /
- 外泌体 /
- 肿瘤微环境
Abstract: Osteosarcoma (OS) is a malignant bone tumor primarily affects in children and adolescents, characterized by rapid progression, high malignancy, and easy metastasis. Metastasis of osteosarcoma often occurs in the early stage of the disease, with the lungs being the primary site of spread, contributing significantly to treatment failure and poor prognosis. Exosomes, extracellular vesicles ranging from 40 to 160 nm in diameter, are secreted by a variety of cells and present in numerous body fluids. They play key roles in intercellular communication and maintaining cell structure. Exosomes contain many bioactive substances, such as protein, lipids, mRNA, and ncRNA, which plays a key role in the distant metastasis of osteosarcoma through intercellular signaling. Among the various ncRNAs, miRNA, lncRNA, and circRNA have been widely studied for their roles in regulating osteosarcoma metastasis at multiple molecular levels. The expression levels of exosomal ncRNA in osteosarcoma can either be increased or decreased, influencing tumor progression and metastasis of osteosarcoma by improving cell invasion and migration, inducing epithelial-mesenchymal transition, promoting angiogenesis, and activating related signal pathways. In terms of drug resistance, exosomes can induce drug resistance in sensitive cells by transmitting ncRNA. Due to their unique biological characteristics, exosomes hold great potential as biomarkers for diagnosis, prognosis, and osteosarcoma metastasis. In recent years, exosomal ncRNAs gained considerable attetion in the mechanistic study and clinical application of osteosarcoma. This paper reviews the role of exosomal ncRNA in osteosarcoma metastasis, chemotherapy resistance, and as a potential biomarker, in order to provide insights into the mechanisms, treatment strategies, and prognosis of osteosarcoma metastasis.
- Non-coding /
- Osteosarcoma /
- Metastasis /
- Exosomes /
- Tumor microenvironment

HTML全文

参考文献(43)

[1]	王文剑, 于秀淳, 韩加, 等. 1 593例骨肉瘤流行病及治疗的回顾性分析[J]. 中华骨科杂志, 2018, 38(18): 1097-1107. doi: 10.3760/cma.j.issn.0253-2352.2018.18.002 WANG W J, YU X C, HAN J, et al. Review and analysis of the treatment of polycentric osteosarcoma in China[J]. Chinese Journal of Orthopaedics, 2018, 38(18): 1097-1107. doi: 10.3760/cma.j.issn.0253-2352.2018.18.002
[2]	ROJAS G A, HUBBARD A K, DIESSNER B J, et al. International trends in incidence of osteosarcoma (1988-2012)[J]. Int J Cancer, 2021, 149(5): 1044-1053. doi: 10.1002/ijc.33673
[3]	SHENG G H, GAO Y, YANG Y, et al. Osteosarcoma and metastasis[J]. Front Oncol, 2021, 11: 780264. DOI: 10.3389/fonc.2021.780264.
[4]	ZHU W G, ZHU L Z, BAO Y Z, et al. Clinical evaluation of neoadjuvant chemotherapy for osteosarcoma[J]. J Buon, 2019, 24(3): 1181-1185.
[5]	ZHANG C, WU H X, XU G J, et al. Incidence, survival, and associated factors estimation in osteosarcoma patients with lung metastasis: a single-center experience of 11 years in Tianjin, China[J]. BMC Cancer, 2023, 23(1): 506. doi: 10.1186/s12885-023-11024-9
[6]	KALLURI R, LEBLEU V S. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478): eaau6977. DOI: 10.1126/science.aau6977.
[7]	YANG Q F, LIU J, WU B, et al. Role of extracellular vesicles in osteosarcoma[J]. Int J Med Sci, 2022, 19(8): 1216-1226. doi: 10.7150/ijms.74137
[8]	LI S L, WANG X H. The potential roles of exosomal noncoding RNAs in osteosarcoma[J]. J cell physiol, 2021, 236(5): 3354-3365. doi: 10.1002/jcp.30101
[9]	SLACK F J, CHINNAIYAN A M. The role of non-coding rnas in oncology[J]. Cell, 2019, 179(5): 1033-1055. doi: 10.1016/j.cell.2019.10.017
[10]	MARQUES T M, GAMA-CARVALHO M. Network approaches to study endogenous RNA competition and its impact on tissue-specific microRNA functions[J]. Biomolecules, 2022, 12(2): 332. doi: 10.3390/biom12020332
[11]	窦沁怡, 王嘉政, 杨滢硕, 等. 外泌体来源非编码RNA在肿瘤微环境中的作用及临床应用价值[J]. 浙江大学学报(医学版), 2023, 52(4): 429-438. DOU Q Y, WANG J Z, YANG Y S, et al. Roles of exosome-derived non-coding RNA in tumor microenvironment and its clinical application[J]. Journal of Zhejiang University(Medical Sciences), 2023, 52(4): 429-438.
[12]	潘寒松, 郭昌军, 梁一民, 等. KLF13上调对骨肉瘤细胞侵袭、迁移及p-AKT表达的影响[J]. 中华全科医学, 2021, 19(12): 2031-2034, 2097. doi: 10.16766/j.cnki.issn.1674-4152.002228 PAN H S, GUO C J, LIANG Y M, et al. Effects of the up-regulation of KLF13 on invasion, migration and p-AKT expression of osteosarcoma cells[J]. Chinese Journal of General Practice, 2021, 19(12): 2031-2034, 2097. doi: 10.16766/j.cnki.issn.1674-4152.002228
[13]	WANG J W, WU X F, GU X J, et al. Exosomal miR-1228 from cancer-associated fibroblasts promotes cell migration and invasion of osteosarcoma by directly targeting SCAI[J]. Oncol Res, 2019, 27(9): 979-986. doi: 10.3727/096504018X15336368805108
[14]	张金山, 鲁厚根, 刘伟, 等. 外泌体携带的miR-142-3p通过靶向COX-2抑制骨肉瘤细胞的增殖和侵袭[J]. 现代肿瘤医学, 2021, 29(15): 2575-2581. ZHANG J S, LU H G, LIU W, et al. The miR-142-3p carried by exosomes inhibits the proliferation and invasion of osteosarcoma cells by targeting COX-2[J]. Journal of Modern Oncology, 2021, 29(15): 2575-2581.
[15]	ZHANG B, YANG Y, TAO R, et al. Exosomes loaded with miR-665 inhibit the progression of osteosarcoma in vivo and in vitro[J]. Am J Transl Res, 2022, 14(10): 7012-7026.
[16]	LI D D, XIA L Y, HUANG P, et al. Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: focusing on partial EMT and regulatory mechanisms[J]. Cell Prolif, 2023, 56(6): e13423. DOI: 10.1111/cpr.13423.
[17]	LIU W S, WANG B Y, DUAN A, et al. Exosomal transfer of miR-769-5p promotes osteosarcoma proliferation and metastasis by targeting DUSP16[J]. Cancer Cell Int, 2021, 21(1): 541. doi: 10.1186/s12935-021-02257-4
[18]	ZHAO A Q, ZHAO Z Q, LIU W L, et al. Carcinoma-associated fibroblasts promote the proliferation and metastasis of osteosarcoma by transferring exosomal LncRNA SNHG17[J]. Am J Transl Res, 2021, 13(9): 10094-10111.
[19]	LIU Y, TANG H J, LI C, et al. Long non-coding RNA and circular RNA and coding RNA profiling of plasma exosomes of osteosarcoma by RNA seq[J]. Sci Data, 2023, 10(1): 395.
[20]	ZHANG H L, WANG J, REN T T, et al. LncRNA CASC15 is upregulated in osteosarcoma plasma exosomes and CASC15 knockdown inhibits osteosarcoma progression by regulating miR-338-3p/RAB14 Axis[J]. Onco Targets Ther, 2020, 13: 12055-12066.
[21]	JI Z Y, SHEN J L, LAN Y J, et al. Targeting signaling pathways in osteosarcoma: mechanisms and clinical studies[J]. MedComm (2020), 2023, 4(4): e308. DOI: 10.1002/mco2.308.
[22]	ZHU G H, XIA Y, ZHAO Z Y, et al. LncRNA XIST from the bone marrow mesenchymal stem cell derived exosome promotes osteosarcoma growth and metastasis through miR-655/ACLY signal[J]. Cancer Cell Int, 2022, 22(1): 330.
[23]	LI F J, CHEN X, SHANG C, et al. Bone marrow mesenchymal stem cells-derived extracellular vesicles promote proliferation, invasion and migration of osteosarcoma cells via the lncRNA MALAT1/miR-143/NRSN2/Wnt/β-Catenin Axis[J]. Onco Targets Ther, 2021, 14: 737-749.
[24]	勾蓉. 肿瘤干细胞信号通路(PI3K/AKT)研究与进展[J]. 哈尔滨医药, 2021, 41(1): 139-141. GOU R. Research and Development in the Signal Pathway of Cancer Stem Cells (PI3K/AKT)[J]. Harbin Medical Journal, 2021, 41(1): 139-141.
[25]	YAN C F, XIA J, QUN W S, et al. Tumor-associated macrophages-derived exo-let-7a promotes osteosarcoma metastasis via targeting C15orf41 in osteosarcoma[J]. Environ toxicol, 2023, 38(6): 1318-1331.
[26]	SHI Z W, WANG K F, XING Y F, et al. CircNRIP1 encapsulated by bone marrow mesenchymal stem cell-derived extracellular vesicles aggravates osteosarcoma by modulating the miR-532-3p/AKT3/PI3K/AKT Axis[J]. Front Oncol, 2021, 11: 658139. DOI: 10.3389/fonc.2021.658139.
[27]	LUO T T, ZHOU X C, JIANG E H, et al. Osteosarcoma cell-derived small extracellular vesicles enhance osteoclastogenesis and bone resorption through transferring microRNA-19a-3p[J]. Front Oncol, 2021, 11: 618662. DOI: 10.3389/fonc.2021.618662.
[28]	葛新滢, 邵露露, 高雪林, 等. 细胞外信号调节激酶1/2信号通路调控细胞侵袭性的研究进展[J]. 中国医学科学院学报, 2023, 45(1): 155-160. GE X Y, SHAO L L, GAO X L, et al. Extracellular Signal-regulated Kinase 1/2 Signaling Regulates Cell Invasion: a Review[J]. Acta Academiae Medicinae Sinicae, 2023, 45(1): 155-160.
[29]	KEREMU A, AILA P, TUSUN A, et al. Extracellular vesicles from bone mesenchymal stem cells transport microRNA-206 into osteosarcoma cells and target NRSN2 to block the ERK1/2-Bcl-xL signaling pathway[J]. Eur J Histochem, 2022, 66(3): 3394.
[30]	PERUT F, RONCUZZI L, ZINI N, et al. Extracellular nanovesicles secreted by human osteosarcoma cells promote angiogenesis[J]. Cancers, 2019, 11(6): 779.
[31]	LI Y S, LIU Q, TIAN J, et al. Angiogenesis process in osteosarcoma: an updated perspective of pathophysiology and therapeutics[J]. Am J Med Sci, 2019, 357(4): 280-288.
[32]	RAIMONDI L, DE LUCA A, GALLO A, et al. Osteosarcoma cell-derived exosomes affect tumor microenvironment by specific packaging of microRNAs[J]. Carcinogenesis, 2020, 41(5): 666-677.
[33]	ZHANG L, CAO H X, GU G H, et al. Exosomal miR-199a-5p inhibits tumorigenesis and angiogenesis by targeting VEGFA in osteosarcoma[J]. Front Oncol, 2022, 12: 884559. DOI: 10.3389/fonc.2022.884559.
[34]	LI Y, ZHAO L, LI X F. Hypoxia and the tumor microenvironment[J]. Technol Cancer Res Treat, 2021, 20: 15330338211036304. DOI: 10.1177/15330338211036304.
[35]	YU X, HU L, LI S Y, et al. Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1 alpha via miR-143-5p[J]. Cell Death Dis, 2019, 10(4): 280.
[36]	LILIENTHAL I, HEROLD N. Targeting molecular mechanisms underlying Treatment efficacy and resistance in osteosarcoma: a review of current and future strategies[J]. Int J Mol Sci, 2020, 21(18): 6885. DOI: 10.3390/ijms21186885.
[37]	FU H C, WU Y J, CHEN J B, et al. Exosomes and osteosarcoma drug resistance[J]. Front Oncol, 2023, 13: 1133726. DOI: 10.3389/fonc.2023.1133726.
[38]	CAI T, ZHANG C L, ZHAN T C. Transfer of exosomal microRNAs confers doxorubicin resistance in osteosarcoma cells[J]. Mol Med Rep, 2023, 27(4): 86.
[39]	PAN Y X, LIN Y F, MI C. Cisplatin-resistant osteosarcoma cell-derived exosomes confer cisplatin resistance to recipient cells in an exosomal circ_103801-dependent manner[J]. Cell biol int, 2021, 45(4): 858-868.
[40]	GALLY T B, ALELUIA M M, BORGES G F, et al. Circulating microRNAs as novel potential diagnostic biomarkers for osteosarcoma: a systematic review[J]. Biomolecules, 2021, 11(10): 1432. DOI: 10.3390/biom11101432.
[41]	YOSHIDA A, FUJIWARA T, UOTANI K, et al. Clinical and functional significance of intracellular and extracellular microRNA-25-3p in osteosarcoma[J]. Acta Med Okayama, 2018, 72(2): 165-174.
[42]	ZHANG K L, DONG C, CHEN M, et al. Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma[J]. Theranostics, 2020, 10(1): 411-425.
[43]	LI Q M, WANG X D, JIANG N, et al. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma[J]. Cancer Med, 2020, 9(17): 6354-6366.